Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Ramucirumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enhertu Reduces Death Risk by 30% vs Ramucirumab Plus Paclitaxel
    Enhertu Reduces Death Risk by 30% vs Ramucirumab Plus Paclitaxel

    31 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250530695013/en/ENHERTU-Reduced-the-Risk-of-Death-by-30-Versus-Ramucirumab-Plus-Paclitaxel-as-a-Second-Line-Therapy-in-Patients-with-HER2-Positive-Unresectable-or-Metastatic-Gastric-Cancer-in-DESTINY-Gastric04-Phase-3-Trial

    BUSINESSWIRE
    31 May 2025
    Share Share
    Eli Lilly`s Biologic Cyramza Receives Suppl Approval in US
    Eli Lilly`s Biologic Cyramza Receives Suppl Approval in US

    07 Apr 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477

    FDA
    07 Apr 2025
    Share Share
    ALX Oncology Reports Q2 2024 Results And Corporate Update
    ALX Oncology Reports Q2 2024 Results And Corporate Update

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2927332/0/en/ALX-Oncology-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    Elevation Oncology Reports Q2 2024 Results And Achievements
    Elevation Oncology Reports Q2 2024 Results And Achievements

    06 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/elevation-oncology-reports-second-quarter-2024-financial-results-and-highlights-recent-business-achievements-302215419.html

    PR NEWSWIRE
    06 Aug 2024
    Share Share
    The China NMPA Approved CYRAMZA for the Treatment of Hepatocellular Carcinoma
    The China NMPA Approved CYRAMZA for the Treatment of Hepatocellular Carcinoma

    09 Oct 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/the-china-nmpa-approved-cyramza-ramucirumab-for-the-treatment-in-patients-with-hepatocellular-carcinoma-301644363.html

    PRNEWSWIRE
    09 Oct 2022
    Share Share
    Eli Lilly's Biologic Cyramza (Ramucirumab) Receives Approval in the U.S.
    Eli Lilly's Biologic Cyramza (Ramucirumab) Receives Approval in the U.S.

    22 Mar 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477

    FDA
    22 Mar 2022
    Share Share